132 related articles for article (PubMed ID: 25751579)
1. Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor.
Schimer J; Pávová M; Anders M; Pachl P; Šácha P; Cígler P; Weber J; Majer P; Řezáčová P; Kräusslich HG; Müller B; Konvalinka J
Nat Commun; 2015 Mar; 6():6461. PubMed ID: 25751579
[TBL] [Abstract][Full Text] [Related]
2. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
3. Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids.
Tanimoto S; Sakai S; Kudo E; Okada S; Matsumura S; Takahashi D; Toshima K
Chem Asian J; 2012 May; 7(5):911-4. PubMed ID: 22378594
[No Abstract] [Full Text] [Related]
4. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
[TBL] [Abstract][Full Text] [Related]
5. A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases.
Tang J; Hartsuck JA
FEBS Lett; 1995 Jun; 367(2):112-6. PubMed ID: 7796905
[TBL] [Abstract][Full Text] [Related]
6. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
[TBL] [Abstract][Full Text] [Related]
7. Oximinoarylsulfonamides as potent HIV protease inhibitors.
Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
[TBL] [Abstract][Full Text] [Related]
8. Synthetic, structural mimetics of the β-hairpin flap of HIV-1 protease inhibit enzyme function.
Chauhan J; Chen SE; Fenstermacher KJ; Naser-Tavakolian A; Reingewertz T; Salmo R; Lee C; Williams E; Raje M; Sundberg E; DeStefano JJ; Freire E; Fletcher S
Bioorg Med Chem; 2015 Nov; 23(21):7095-109. PubMed ID: 26474665
[TBL] [Abstract][Full Text] [Related]
9. Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation.
Sluis-Cremer N; Arion D; Abram ME; Parniak MA
Int J Biochem Cell Biol; 2004 Sep; 36(9):1836-47. PubMed ID: 15183348
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the HIV-1 protease dimer with interface peptides: structural studies using NMR spectroscopy combined with [2-(13)C]-Trp selective labeling.
Frutos S; Rodriguez-Mias RA; Madurga S; Collinet B; Reboud-Ravaux M; Ludevid D; Giralt E
Biopolymers; 2007; 88(2):164-73. PubMed ID: 17236209
[TBL] [Abstract][Full Text] [Related]
11. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes.
Lindhofer H; von der Helm K; Nitschko H
Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565
[TBL] [Abstract][Full Text] [Related]
12. Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold.
Schimer J; Cígler P; Veselý J; Grantz Šašková K; Lepšík M; Brynda J; Rezáčová P; Kožíšek M; Císařová I; Oberwinkler H; Kraeusslich HG; Konvalinka J
J Med Chem; 2012 Nov; 55(22):10130-5. PubMed ID: 23050738
[TBL] [Abstract][Full Text] [Related]
13. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
Lu D; Sham YY; Vince R
Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
[TBL] [Abstract][Full Text] [Related]
16. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
17. New heteroaryl carbamates: Synthesis and biological screening in vitro and in mammalian cells of wild-type and mutant HIV-protease inhibitors.
Tramutola F; Armentano MF; Berti F; Chiummiento L; Lupattelli P; D'Orsi R; Miglionico R; Milella L; Bisaccia F; Funicello M
Bioorg Med Chem; 2019 May; 27(9):1863-1870. PubMed ID: 30922618
[TBL] [Abstract][Full Text] [Related]
18. Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro.
McPhee F; Caldera PS; Bemis GW; McDonagh AF; Kuntz ID; Craik CS
Biochem J; 1996 Dec; 320 ( Pt 2)(Pt 2):681-6. PubMed ID: 8973584
[TBL] [Abstract][Full Text] [Related]
19. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of symmetric inhibitors of HIV-1 protease.
Erickson J; Kempf D
Arch Virol Suppl; 1994; 9():19-29. PubMed ID: 8032250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
